127 related articles for article (PubMed ID: 2752507)
1. Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer.
Reece PA; Stafford I; Davy M; Morris R; Freeman S
Cancer Chemother Pharmacol; 1989; 24(4):256-60. PubMed ID: 2752507
[TBL] [Abstract][Full Text] [Related]
2. Two- versus 24-hour infusion of cisplatin: pharmacokinetic considerations.
Reece PA; Stafford I; Abbott RL; Anderson C; Denham J; Freeman S; Morris RG; Gill PG; Olweny CL
J Clin Oncol; 1989 Feb; 7(2):270-5. PubMed ID: 2536803
[TBL] [Abstract][Full Text] [Related]
3. Disposition of unchanged cisplatin in patients with ovarian cancer.
Reece PA; Stafford I; Davy M; Freeman S
Clin Pharmacol Ther; 1987 Sep; 42(3):320-5. PubMed ID: 3621787
[TBL] [Abstract][Full Text] [Related]
4. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
[TBL] [Abstract][Full Text] [Related]
5. Disposition of total and free cisplatin on two consecutive treatment cycles in patients with ovarian cancer.
Erlichman C; Soldin SJ; Thiessen JJ; Sturgeon JF; Fine S
Cancer Chemother Pharmacol; 1987; 19(1):75-9. PubMed ID: 3815729
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
Erdlenbruch B; Nier M; Kern W; Hiddemann W; Pekrun A; Lakomek M
Eur J Clin Pharmacol; 2001 Aug; 57(5):393-402. PubMed ID: 11599657
[TBL] [Abstract][Full Text] [Related]
7. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity.
Reece PA; Stafford I; Russell J; Khan M; Gill PG
J Clin Oncol; 1987 Feb; 5(2):304-9. PubMed ID: 3806171
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin pharmacokinetics using a five-day schedule during repeated courses of chemotherapy in germ cell tumors.
Bonetti A; Franceschi T; Apostoli P; Messori A; Sperotto L; Cetto GL; Molino A; Leone R
Ther Drug Monit; 1995 Feb; 17(1):25-32. PubMed ID: 7725373
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin disposition in children and adolescents with cancer.
Crom WR; Evans WE; Pratt CB; Senzer N; Denison M; Green AA; Hayes FA; Yee GC
Cancer Chemother Pharmacol; 1981; 6(1):95-9. PubMed ID: 7196807
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacokinetics study of intraperitoneal cisplatin in ovarian carcinoma].
Han GR; Cai GF
Zhonghua Fu Chan Ke Za Zhi; 1993 Apr; 28(4):224-6, 254. PubMed ID: 8404307
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of platinum in cancer patients treated with cisplatin at different doses.
Fracasso ME; Apostoli P; Benoni G; Bonetti A; Griso C; Leone R
Drugs Exp Clin Res; 1987; 13(6):367-72. PubMed ID: 3652926
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancer.
Reece PA; Morris RG; Bishop JF; Olver IN; Raghavan D
Cancer Res; 1987 Jun; 47(11):2996-9. PubMed ID: 2952262
[TBL] [Abstract][Full Text] [Related]
13. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin.
Vermorken JB; van der Vijgh WJ; Klein I; Gall HE; van Groeningen CJ; Hart GA; Pinedo HM
Clin Pharmacol Ther; 1986 Feb; 39(2):136-44. PubMed ID: 3943271
[TBL] [Abstract][Full Text] [Related]
15. Clinical and pharmacokinetic study of intraperitoneal cisplatin at two dose levels: 100 mg/m2 alone or 200 mg/m2 with i.v. sodium thiosulfate.
Canal P; de Forni M; Chatelut E; Chevreau C; Johnson NP; Houin G; Bugat R
Acta Med Austriaca; 1989; 16(3-4):84-6. PubMed ID: 2609919
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetics of high-dose cisplatin administration (relationship between pharmacokinetics and administration schedule)].
Yamamoto N; Yanagi K; Matuyama H; Shimizu K; Mitsui H; Shimabukuro T; Yamamoto M; Sakatoku J; Fujita T; Matsuoka K
Hinyokika Kiyo; 1987 Nov; 33(11):1760-5. PubMed ID: 3445857
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program.
Nagai N; Ogata H; Wada Y; Tsujino D; Someya K; Ohno T; Masuhara K; Tanaka Y; Takahashi H; Nagai H; Kato K; Koshiba Y; Igarashi T; Yokoyama A; Kinameri K; Kato T; Kurita Y
J Clin Pharmacol; 1998 Nov; 38(11):1025-34. PubMed ID: 9824784
[TBL] [Abstract][Full Text] [Related]
18. Two-cycle cisplatin kinetics in patients with ovarian and mammary cancer.
Leone R; Benoni G; Apostoli P; Bonetti A; Griso C; Fracasso ME
Ther Drug Monit; 1987 Dec; 9(4):374-7. PubMed ID: 3424403
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacokinetics of cisplatin in long-term hemodialysis treatment].
Sturn W; Sanwald R; Ehninger G
Dtsch Med Wochenschr; 1989 Mar; 114(9):337-9. PubMed ID: 2920679
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer].
Deng C; Huang R; Lian L
Zhonghua Fu Chan Ke Za Zhi; 1996 Mar; 31(3):159-62. PubMed ID: 8758790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
